Market Newsdesk

TORONTO, Dec. 10, 2020 /CNW/ – Trading resumes in:

Company: Dye & Durham Limited

TSX Symbol: DND

All Issues: Yes

Resumption (ET): 9:45 AM

IIROC can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts are implemented to ensure a fair and orderly market. IIROC is the national self-regulatory organization which oversees all investment dealers and trading activity on debt and equity marketplaces in Canada.

SOURCE Investment Industry Regulatory Organization of Canada (IIROC) – Halts/Resumptions

BETHESDA, Md., Dec. 10, 2020 /PRNewswire/ — Walker & Dunlop (NYSE: WD) will host a virtual Investor Day this morning to unveil its Drive to ’25 strategy and provide five-year operational and financial targets.

Willy Walker, Chairman and CEO commented, “We have built a long track record of exceptional growth with our success grounded in three core principles: People, Brand and Technology. We have worked tirelessly to build out our platform with the very best people in the industry, grow our brand and reputation as a company with all of the capabilities and resources of a large firm but with the touch and feel of a family company. These principles enabled us to exceed many of the key targets that we established as part of our Vision 2020 plan, and will continue to drive the achievement of our ambitious long-term goals.”  

Mr. Walker continued, “We are excited to unveil our new Drive to ’25 strategy that will enable Walker & Dunlop to continue on our current growth trajectory and carry out our mission of becoming the premier commercial real estate finance company in the United States. Our core strategy is centered around growing debt financing volume, expanding our property sales platform, and building investment banking capabilities. These initiatives will all be supported by our continued commitment to harness the power of technology, including artificial intelligence, data analytics, and machine learning, to enable our team to gain deeper insight into clients’ portfolios and assets. We believe that our focus on scaling the platform through investments in our people, brand, and technology, will enable us to grow our topline and drive profitability to continue creating sustainable, long-term shareholder value. We also recognize we must think bigger and are committed to critical ESG initiatives that position Walker & Dunlop as an industry leader while we carry out our role of financing where Americans live, work, play and shop.”

Drive to ’25 Targets

During Walker & Dunlop’s Investor Day, management will outline the following five-year operational and financial targets to be achieved by year-end 2025 to deliver significant growth and long-term shareholder value:

Walker & Dunlop’s 2020 Virtual Investor Day

Today’s Investor Day will feature presentations from Willy Walker, Walker & Dunlop’s Chairman and CEO, Steve Theobald, EVP & Chief Financial Officer, Sheri Thompson, EVP of FHA Finance, Kris Mikkelsen, EVP of Investment Sales, Greg Florkowski, EVP of Business Development, and TJ Edwards, Managing Director of Proprietary Capital.  Following the presentations, management will conduct a live Q&A session.

• When: Thursday, December 10, 2020 
• Time: 10:00 a.m. Eastern Time. The event is expected to conclude at approximately 12:30 p.m. Eastern Time.
• Analysts and investors may access the webcast via the link below: https://walkerdunlop.zoom.us/webinar/register/WN_mFc4-mQFT7CvNuiuOh1_2g or by dialing +1-408-901-0584, Webinar ID 950 9227 0431, Passcode 857934
• Presentation materials for the Investor Day are posted on the Investor Relations section of the company’s website. A webcast replay of the event will also be available on the Investor Relations section of the company’s website at http://investors.walkerdunlop.com/.

About Walker & Dunlop

Walker & Dunlop (NYSE: WD), headquartered in Bethesda, Maryland, is one of the largest commercial real estate finance companies in the United States. The company provides a comprehensive range of capital solutions for all commercial real estate asset classes, as well as investment sales brokerage services to owners of multifamily properties. Walker & Dunlop is included on the S&P SmallCap 600 Index and was ranked as one of FORTUNE Magazine’s Fastest Growing Companies in 2014, 2017, and 2018. Walker & Dunlop’s 950+ professionals in 41 offices across the nation have an unyielding commitment to client satisfaction.

Forward-Looking Statements

Some of the statements contained in this press release may constitute forward-looking statements within the meaning of the federal securities laws. Forward-looking statements relate to expectations, projections, financial targets, plans and strategies, anticipated events or trends and similar expressions concerning matters that are not historical facts. In some cases, you can identify forward-looking statements by the use of forward-looking terminology such as “will,” “believe” or “target” or similar words or phrases that are predictions of or indicate future events or trends and which do not relate solely to historical matters. You can also identify forward-looking statements by discussions of strategy, plans, or intentions. The forward-looking statements contained in this press release reflect our current views about future events and are subject to numerous known and unknown risks, uncertainties, assumptions and changes in circumstances that may cause actual results to differ significantly from those expressed or contemplated in any forward-looking statement. While forward-looking statements reflect our good faith projections, assumptions and expectations, they are not guarantees of future results. Furthermore, we disclaim any obligation to publicly update or revise any forward-looking statement to reflect changes in underlying assumptions or factors, new information, data or methods, future events or other changes, except as required by applicable law. Factors that could cause our results to differ materially include, but are not limited to:
(1) the impact of the COVID-19 pandemic on the company’s business, results of operations, and financial condition, including due to its principal and interest advance obligations on Fannie Mae and Ginnie Mae loans it services, and the domestic economy, (2) general economic conditions and multifamily and commercial real estate market conditions, (3) regulatory and/or legislative changes to Freddie Mac, Fannie Mae or HUD, (4) our ability to retain and attract loan originators and other professionals, and (5) changes in federal government fiscal and monetary policies, including any constraints or cuts in federal funds allocated to HUD for loan originations.
For a further discussion of these and other factors that could cause future results to differ materially from those expressed or contemplated in any forward-looking statements, see the section titled “Risk Factors” in our most recent Annual Report on Form 10-K and any updates or supplements in subsequent Quarterly Reports on Form 10-Q and our other filings with the SEC. Such filings are available publicly on our Investor Relations web page at www.walkerdunlop.com.

Non-GAAP Financial Measures

To supplement our financial statements presented in accordance with United States generally accepted accounting principles (“GAAP”), the company uses adjusted EBITDA, a non-GAAP financial measure. The presentation of adjusted EBITDA is not intended to be considered in isolation or as a substitute for, or superior to, the financial information prepared and presented in accordance with GAAP. When analyzing our operating performance, readers should use adjusted EBITDA in addition to, and not as an alternative for, net income. Adjusted EBITDA represents net income before income taxes, interest expense on our term loan facility, and amortization and depreciation, adjusted for provision (benefit) for credit losses net of write-offs, stock-based incentive compensation charges, and non-cash revenues such as the fair value of expected net cash flows from servicing, net. Because not all companies use identical calculations, our presentation of adjusted EBITDA may not be comparable to similarly titled measures of other companies. Furthermore, adjusted EBITDA is not intended to be a measure of free cash flow for our management’s discretionary use, as it does not reflect certain cash requirements such as tax and debt service payments. The amounts shown for adjusted EBITDA may also differ from the amounts calculated under similarly titled definitions in our debt instruments, which are further adjusted to reflect certain other cash and non-cash charges that are used to determine compliance with financial covenants.

We use adjusted EBITDA to evaluate the operating performance of our business, for comparison with forecasts and strategic plans and for benchmarking performance externally against competitors. We believe that this non-GAAP measure, when read in conjunction with the company’s GAAP financials, provides useful information to investors by offering

• the ability to make more meaningful period-to-period comparisons of the company’s on-going operating results;
• the ability to better identify trends in the company’s underlying business and perform related trend analyses; and
• a better understanding of how management plans and measures the company’s underlying business.

We believe that adjusted EBITDA has limitations in that it does not reflect all of the amounts associated with the company’s results of operations as determined in accordance with GAAP and that adjusted EBITDA should only be used to evaluate the company’s results of operations in conjunction with net income. For more information on adjusted EBITDA, refer to the section of this press release below titled “Adjusted Financial Metric Reconciliation to GAAP.”

View original content:http://www.prnewswire.com/news-releases/walker–dunlop-unveils-its-drive-to-25-strategy-to-become-the-premier-commercial-real-estate-finance-company-in-the-us-301190506.html

SOURCE Walker & Dunlop, Inc.

ATLANTA, Dec. 10, 2020 /PRNewswire/ — HI-BRIDGE HIE has selected NextGen^® Health Data Hub (HDH), a cloud-based health information exchange (HIE) platform that supports the secure sharing of patient health data aggregated from multiple sources.

NextGen HDH allows HIE administrators to establish rules-driven data exchange to facilitate the automated routing of patient information throughout the community of care. The solution includes built-in patient matching, an API-first design, support for behavioral health data protection, and a provider portal. HDH supports all the clinical data types in use by in-patient and ambulatory health systems and its robust data normalization capabilities ensure that all connected systems can interoperate successfully.

“We selected NextGen Health Data Hub because it is best suited to meet our needs and the needs of our providers. Our goal is to consistently improve patient access to care, access to health data, and to drive an overall better patient and provider experience. Out of the box, HDH provides the platform for us to fulfill our goals,” said Dominic H. Mack, M.D., MBA.

“We are proud to partner with HI-BRIDGE to support the future of data exchange in the greater Atlanta region and we are confident that the selection of Health Data Hub can help facilitate greater interoperability, data access, and improved clinical insights for all connected providers,” said John Beck, chief solutions officer for NextGen Healthcare.

Carmen Hughes, Health IT Director stated, “We are excited to embark on this new partnership with NextGen Healthcare and their HDH solution as we advance our HIE platform to better support our members, and scalable to align with our growth initiatives.  Additionally, our technical services partner, TangoSquared, will provide the necessary know how to take advantage HDH’s vast patient and clinical searches, improved system performance, enhanced EHR interoperability, and improved reporting.”

“Working with HI-BRIDGE and NextGen Healthcare to implement HDH has truly been an exceptional experience. Both organizations are committed to bringing the best in class solutions to their clients. As a technology solutions provider we believe HDH has no equal with its cloud-based, API first platform. It’s a modern platform built with tomorrow in mind,” said Thomas Theriault, Founder and CEO, TangoSquared.

About HI-BRIDGE HIE:  Established in 2014, HI-BRIDGE HIE, is a mission-based Regional Health Information Exchange (formerly Georgia HealthConnect) created to provide interoperability through integrated technology and clinical support services to meet the needs of smaller practices, hospitals and health systems for the electronic exchange of patient clinical information.  HI-BRIDGE HIE is member affiliate of Georgia’s state HIE, Georgia Health Information Network (GaHIN), through which bi-directional data exchange enables users to have access to statewide and nationwide patient clinical record data at the point of patient care. HI-BRIDGE HIE is based out of the National Center for Primary Care at the Morehouse School of Medicine, in Atlanta, GA. Learn more at hibridges.org 

About NextGen Healthcare:

NextGen Healthcare, Inc. (Nasdaq: NXGN) is a leading provider of healthcare technology solutions. We are empowering the transformation of ambulatory care—partnering with medical, behavioral and dental providers in their journey to value-based care to make healthcare better for everyone. We go beyond EHR and PM. Our integrated solutions help increase clinical productivity, enrich the patient experience, and ensure healthy financial outcomes. We believe in better. Learn more at nextgen.com, and follow us on Facebook, Twitter, LinkedIn, YouTube and Instagram.

About TangoSquared:  Founded in 2006, TangoSquared is a veteran-owned design and development agency headquartered in Syracuse NY. Our services include UX design and implementation, application architecture and development, as well as branding and marketing communications. Please visit https://tangosquared.com

Contact:

HI-BRIDGE HIE 
Carmen Hughes 
(404) 756-8801 
[email protected]

NextGen Healthcare 
Tami Stegmaier 
(949) 237-6083 
[email protected]   

TangoSquared 
Thomas Theriault 
(315) 720-5988 
[email protected]

View original content to download multimedia:http://www.prnewswire.com/news-releases/hi-bridge-hie-selects-nextgen-health-data-hub-as-its-health-information-exchange-platform-301190503.html

SOURCE HI-BRIDGE HIE

FOSTER CITY, Calif. and BAD HOMBURG, Germany, Dec. 10, 2020 /PRNewswire/ — Gilead Sciences, Inc. (Nasdaq: GILD) and MYR GmbH, a German biotechnology company focused on the development and commercialization of therapeutics for the treatment of chronic hepatitis delta virus (HDV), today announced that the companies have entered into a definitive agreement pursuant to which Gilead will acquire MYR for approximately €1.15 billion in cash, payable upon closing of the transaction plus a potential future milestone payment of up to €300 million (both payments subject to customary adjustments).

The acquisition will provide Gilead with Hepcludex^™ (bulevirtide), which was conditionally approved by the European Medicines Agency (EMA) for the treatment of chronic HDV infection in adults with compensated liver disease in July 2020. MYR has since launched Hepcludex in France, Germany and Austria, and continues to prepare for launch in certain other markets throughout 2021. It is expected that this transaction will accelerate the global launch of Hepcludex. Hepcludex is a first-in-class treatment for HDV that blocks viral entry into liver cells through binding to NTCP. It is the first and currently the only medicine conditionally approved for HDV by the EMA, and MYR anticipates submission for accelerated approval in the United States in the second half of 2021. The U.S. Food and Drug Administration (FDA) has granted the medicine both Orphan Drug and Breakthrough Therapy designations for chronic HDV infection.

HDV is the most severe form of viral hepatitis and can have mortality rates as high as 50% within 5 years in cirrhotic patients. HDV occurs only as a co-infection in individuals who have hepatitis B virus (HBV). At least 12 million people worldwide are likely currently co-infected with HDV and HBV. HDV co-infection leads to more serious liver disease than HBV alone and is associated with a faster progression to liver fibrosis, cirrhosis, hepatic decompensation and an increased risk of liver cancer and death. In the United States and Europe, there are collectively more than 230,000 people living with HDV, which remains underdiagnosed globally.

“HDV is a devastating disease with high unmet medical need. With Hepcludex we have the opportunity to address that need with a first-in-class therapy,” said Daniel O’Day, Chairman and Chief Executive Officer, Gilead Sciences. “We look forward to working with the team at MYR to realize the full potential of Hepcludex for patients with HDV worldwide. This will build on the work that Gilead has been doing for almost two decades to innovate and improve therapies for viral hepatitis.”

“We are proud of our achievement in bringing Hepcludex from preclinical stage to patients in need within such a short timeframe,” said Dmitry Popov, Chief Executive Officer, MYR GmbH. “We are excited to join Gilead, whose experience in the hepatitis field and global infrastructure will realize the full potential of Hepcludex and provide access to as many patients as possible around the world with this debilitating disease.”

Hepcludex (bulevirtide) is an entry inhibitor that binds to NTCP, an essential HBV and HDV receptor on hepatocytes, blocking the ability of HDV to enter hepatocytes. Bulevirtide has been tested in more than 500 patients in completed and ongoing clinical studies. The benefit of bulevirtide has been demonstrated by an effective reduction of HDV RNA levels and improvement of liver inflammation. In the MYR202 study, which was a controlled, open-label Phase 2 study, 54 of 90 patients treated with bulevirtide plus tenofovir disoproxil fumarate (TDF) had at least a 2 log₁₀ HDV RNA decline or undetectable HDV RNA at week 24 versus 1 of 28 patients given TDF alone. Almost half of patients treated with bulevirtide and TDF also showed a normalization in the blood levels of the liver enzyme ALT, indicating an improvement of liver disease, as compared to 7% of patients who received TDF alone.

In the Phase 2 MYR203 study evaluating a 48-week treatment course of bulevirtide, a further 15 patients were treated with Hepcludex 2mg daily monotherapy for 48 weeks. In this limited dataset, the safety and efficacy profiles were similar to patients treated for 24 weeks in combination with TDF in the MYR202 study. Interim 24-week data from the ongoing Phase 3 study MYR301 of bulevirtide is anticipated in the first half of 2021 and is expected to serve as the basis for filing in the United States.

Terms of the Agreement

Under the terms of the sale and purchase agreement, Gilead will acquire MYR for approximately €1.15 billion in cash, payable upon closing of the transaction plus a potential future milestone payment of up to €300 million upon U.S. FDA approval (both payments subject to customary adjustments). After the closing, in addition to enhancing Gilead’s revenue growth, the acquisition of MYR is expected to be neutral to non-GAAP EPS in the first two years after close and moderately accretive thereafter. Closing of the transaction is subject to expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act and receipt of merger control approvals in certain European jurisdictions.

Goldman Sachs & Co. LLC is acting as financial advisor to Gilead. UBS Europe SE is acting as financial advisor to MYR. Gibson, Dunn & Crutcher, Mayer Brown LLP, and Flick Gocke Schaumburg are serving as legal counsel to Gilead and Freshfields Bruckhaus Deringer Rechtsanwälte Steuerberater PartG mbB is serving as legal counsel to MYR.

Additional Information

Additional information about the agreement can be found at Gilead’s Investors page at http://investors.gilead.com.

About Hepcludex (bulevirtide)

Hepcludex is the first drug conditionally approved for the treatment of HDV in adults with compensated liver disease in Europe. Hepcludex blocks the NTCP receptor on the surface of hepatocytes and prevents the entry of HBV/HDV into hepatocytes and viral spread within the liver. Hepcludex is administered subcutaneously as monotherapy or in patients being treated with a nucleoside/nucleotide analogue. Hepcludex has received Orphan Drug Designation for treatment of HDV infection from EMA and from the FDA. Hepcludex has been granted PRIority MEdicines (PRIME) scheme eligibility by EMA for the treatment of HDV infection and Breakthrough Therapy designation by the FDA. Bulevirtide is an investigational agent in the U.S. and outside of the European Economic Area; in these regions the safety and efficacy have not been established.

The most commonly reported serious adverse reaction was an exacerbation of hepatitis after treatment discontinuation, and most commonly reported adverse reactions were an increase in bile salts and injection site reactions. The safety and efficacy of Hepcludex in patients with decompensated cirrhosis have not been established and therefore its use is not recommended. See the Summary of Product Characteristics, which includes contraindications and special warnings and precautions, for further product information, available at  www.eua.europa.eu. 

About MYR GmbH

MYR GmbH is a private, commercial stage biotechnology company headquartered in Bad Homburg, Germany. The company is dedicated to the development of bulevirtide; bulevirtide is a first-in-class entry inhibitor which binds to the NTCP receptor for HDV and other indications. MYR started operations in 2011 and has been supported by its founders, private and venture capital investors including the High-Tech-Gründerfonds (www.htgf.de/en/). For more information on MYR, please visit the company’s website at www.myr-pharma.com.

About Gilead Sciences

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California. For more information on Gilead Sciences, please visit the company’s website at www.gilead.com.

Gilead Forward-Looking Statements

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including the ability of the parties to complete the transaction in a timely manner or at all; the possibility that various closing conditions for the transaction may not be satisfied or waived, including the possibility that a governmental entity may prohibit, delay or refuse to grant approval for the consummation of the transaction; uncertainties relating to the timing or outcome of any filings and approvals relating to the transaction; difficulties or unanticipated expenses in connection with integrating the companies, including the effects of the transaction on relationships with employees, other business partners or governmental entities; the risk that Gilead may not realize the expected benefits of this transaction; the ability of Gilead to advance MYR GmbH’s product pipeline and successfully commercialize Hepcludex; the ability of the parties to initiate and complete clinical trials involving Hepcludex in the currently anticipated timelines or at all; the possibility of unfavorable results from one or more of such trials involving Hepcludex; uncertainties relating to regulatory applications and related filing and approval timelines, including the risk that FDA may not approve Hepcludex for the treatment of HDV in the anticipated timelines or at all, and any marketing approvals, if granted, may have significant limitations on its use; any assumptions underlying any of the foregoing; and other risks and uncertainties detailed from time to time in Gilead’s periodic reports filed with the U.S. Securities and Exchange Commission (the “SEC”), including current reports on Form 8-K, quarterly reports on Form 10-Q and annual reports on Form 10-K.  These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements.  All statements other than statements of historical fact are statements that could be deemed forward-looking statements.  Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties and are cautioned not to place undue reliance on these forward-looking statements. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation and disclaim any intent to update any such forward-looking statements.

View original content:http://www.prnewswire.com/news-releases/gilead-sciences-to-acquire-myr-gmbh-301190500.html

SOURCE MYR Pharmaceuticals